Clinical trials: Edematous
Visual Impairment, Macular Edema
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)
This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant after 6 months of treatment. In the study arm Ranibizumab will be given monthly in a pro re nata scheme whereas the comparator…
- Conditions
- Visual Impairment, Macular Edema, Branch Retinal Vein Occlusion
- Trial name
- COMRADE-B (NCT01396057)
- Testing
- Ranibizumab, Dexamethasone Implant
- Where
- 66 sites in Czechia, Germany and 3 more
- Volunteers
- 244 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema
The study involves the enrollment of patients over 18 years of age with diabetic macular edema involving the center of the macula who have not already been given maximal laser treatment.
- Trial name
- Peribulbar (NCT00369486)
- Testing
- Focal laser photocoagulation, 40mg triamcinolone, 20mg triamcinolone
- Volunteers
- 113 people
- Sponsor
- Jaeb Center for Health Research
Meniere's Disease
A 6-Month Extension Study of OTO-104 in Meniere's Disease
This is an open-label extension study of a single intratympanic injection of OTO-104 given every 3 months for a total of 2 injections.
- Trial name
- NCT02768662
- Testing
- OTO-104
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Otonomy, Inc.
Diabetic Macular Edema
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or as monotherapy in Asian patients with visual impairment due to Diabetic Macular…
- Trial name
- REVEAL (NCT00989989)
- Testing
- Ranibizumab, Laser photocoagulation
- Where
- 35 sites in China, Hong Kong and 4 more
- Volunteers
- 396 people
- Sponsor
- Novartis
Macular Edema, Diabetic
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
The study hypothesis under test is that administration of the CCR2/5 antagonist has the potential to be as effective as the current treatment options for subjects with diabetic macular edema.
- Trial name
- NCT01994291
- Testing
- Ranibizumab, PF-04634817
- Where
- 63 sites in United States, Bulgaria and 7 more
- Volunteers
- 199 people
- Sponsor
- Pfizer
Acute Heart Failure, Diuretics Drug Reactions
Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment
This is a pragmatic, multicenter, interventional, parallel-arm, randomized, open-label trial to investigate whether a diuretic regimen, based on serial assessment of sodium concentration (UNa) on spot urine samples after diuretic…
- Trial name
- DECONGEST (NCT05411991)
- Testing
- UNa measurement after intravenous loop diuretic bolus, Intravenous acetazolamide 500 mg OD, Intravenous bumetanide TID
- Where
- 2 sites in Belgium
- Volunteers
- 107 people
- Sponsor
- Vrije Universiteit Brussel
Diabetic Macular Edema
Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema
The purpose of this study is to assess the safety and tolerability of MP0112 (a novel, potentially long acting VEGF inhibitor) in patients with diabetic retinal edema.
- Trial name
- NCT01042678
- Testing
- MP0112
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Allergan
Edematous Fibrosclerotic Panniculopathy, Cellulite
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).
- Trial name
- NCT02942160
- Testing
- Collagenase Clostridium Histolyticum
- Where
- 15 sites in United States
- Volunteers
- 259 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Diabetic Macular Edema
Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema
This study is designed to demonstrate the safety and tolerability of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema associated with diabetes mellitus.
- Trial name
- HULK (NCT02949024)
- Testing
- IVT Aflibercept, SC CLS-TA
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Clearside Biomedical, Inc.
Diabetic Macular Edema
A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
This is a multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, three parallel group, 36-week study in participants with center-involving diabetic macular edema (DME).
- Trial name
- BOULEVARD (NCT02699450)
- Testing
- Faricimab, Ranibizumab
- Where
- 60 sites in United States
- Volunteers
- 229 people
- Sponsor
- Hoffmann-La Roche
Macular Edema
A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)
This study will use retrospective data to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular oedema due to Retinal Vein Occlusion (RVO).
- Trial name
- NCT01445626
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- Germany
- Volunteers
- 87 people
- Sponsor
- Allergan
Retinal Vein Occlusion, Macular Oedema
Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion
The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received…
- Trial name
- NCT01566526
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- Belgium
- Volunteers
- 26 people
- Sponsor
- Allergan
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Researchers are looking for a better way to treat participants who have diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD). DME is a diabetes-related eye disorder.
- Trial name
- DEUTERON (NCT06591598)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 51 people
- Sponsor
- Bayer
Diabetic Macular Edema, Retinal Disease
Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema.
- Conditions
- Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus
- Trial name
- NCT06011798
- Testing
- Aflibercept, foselutoclax
- Where
- 19 sites in United States
- Volunteers
- 52 people
- Sponsor
- Unity Biotechnology, Inc.
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension
This study was designed to compare the efficacy, tolerability, and safety of the combination valsartan/amlodipine 160/5 mg versus amlodipine 10 mg in patients with essential hypertension not adequately controlled (defined as mean…
- Trial name
- NCT00437645
- Testing
- Valsartan 160 mg capsules, Amlodipine 5 mg capsules
- Where
- 12 sites in Argentina, Chile and 10 more
- Volunteers
- 1,183 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure; With Decompensation
Compression Wraps as Adjuvant Therapy in Management of Acute Systolic Heart Failure
There will be two populations in this study: control group, and intervention group. These groups will undergo propensity matching to account for confounders and minimize selection bias.
- Trial name
- CATAS-HF (NCT04095416)
- Testing
- ACE compression wrap
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Henry Ford Health System
Visual Impairment, Macular Edema
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)
This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant® after 6 months of treatment. In the study arm Lucentis will be given monthly in a pro re nata scheme whereas the comparator…
- Conditions
- Visual Impairment, Macular Edema, Central Retinal Vein Occlusion
- Trial name
- COMRADE-C (NCT01396083)
- Testing
- Ranibizumab
- Where
- 64 sites in Germany, Hungary and 2 more
- Volunteers
- 243 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Branch Retinal Vein Occlusion
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at…
- Trial name
- BALATON (NCT04740905)
- Testing
- Faricimab, Aflibercept
- Where
- 150 sites in United States, Argentina and 20 more
- Volunteers
- 553 people
- Sponsor
- Hoffmann-La Roche
Macular Edema
Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema
This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).
- Trial name
- NCT01492400
- Testing
- dexamethasone Intravitreal Implant, ranibizumab
- Where
- 13 sites in United States, Belgium and 10 more
- Volunteers
- 363 people
- Sponsor
- Allergan
Retinal Vein Occlusion, Macula Edema
TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
Randomized, double-masked trial designed to investigate the use of TLC399 (ProDex) in subjects with macular edema due to CRVO or BRVO.
- Trial name
- NCT03093701
- Testing
- TLC399 (ProDex)
- Where
- 20 sites in United States
- Volunteers
- 31 people
- Sponsor
- Taiwan Liposome Company